BioMed Research International

BioMed Research International / 2010 / Article

Research Article | Open Access

Volume 2010 |Article ID 904767 |

Cord C. Uphoff, Sabine A. Denkmann, Klaus G. Steube, Hans G. Drexler, "Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in Human and Other Primate Cell Lines", BioMed Research International, vol. 2010, Article ID 904767, 23 pages, 2010.

Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in Human and Other Primate Cell Lines

Academic Editor: Ellen Collisson
Received30 Sep 2009
Revised21 Jan 2010
Accepted10 Feb 2010
Published29 Apr 2010


The high prevalence of contaminated cell cultures suggests that viral contaminations might be distributed among cultures. We investigated more than 460 primate cell lines for Epstein-Barr (EBV), hepatitis B (HBV), hepatitis C (HCV), human immunodeficiency virus type 1 (HIV-1), human T-cell leukemia/lymphoma virus I and II (HTLV-I/-II), and squirrel monkey retrovirus (SMRV) infections for risk assessment. None of the cell lines were infected with HCV, HIV-1, or HTLV-I/-II. However, one cell line displayed reverse transcriptase activity. Thirty-nine cell lines harbored EBV DNA sequences. Studies on the lytic phase of EBV revealed that five cell lines produce EBV particles and six further cell lines produced EBV upon stimulation. One cell line contained an integrated HBV genome fragment but showed no virus production. Six cell lines were SMRV-infected. Newly established cell lines should be tested for EBV infections to detect B-lymphoblastoid cell lines (B-LCL). B-LCLs established with EBV from cell line B95-8 should be tested for SMRV infections.

1. Introduction

Human primary cell cultures and cell lines have become fundamental tools for basic research in numerous life science faculties as well as for the production of bioactive reagents in biomedicine and biotechnology. They are already used for several decades and frozen cell cultures or blood and tissue samples obtained many years ago can be found in numerous laboratories. As known from experience in the transfusion and transplantation medicine, human cells can harbor a number of different human pathogens and conveyed a potential risk for the recipients to become infected before extensive screenings of the material were accomplished. In particular, human pathogenic viruses like human immunodeficiency virus type 1 (HIV-1), human T-cell leukemia/lymphoma virus type I and II (HTLV-I and -II), and hepatitis viruses, for example, hepatitis B virus (HBV) and hepatitis C virus (HCV), are found in human donor and patient material [1]. Cell lines were usually established from patient material which might similarly be infected with those viruses or perhaps with viruses linked to specific tumors, for example, human herpes virus type 8 (HHV-8) or novel types of papilloma viruses [2]. A considerable percentage of cell lines was established before viral contaminations had been routinely assayed or even before those viruses had been discovered. Additionally, the risk of emerging pathogens has to be kept under constant review [3].

Indeed, some cell lines are known to harbor human pathogenic viruses, among them the well-known and widely distributed HeLa cell line which contains the human papilloma virus integrated into its genome [4]. Besides the infection of the primary material which may be traced back to the donor, contaminations of cell cultures can also be introduced secondarily by laboratory personnel or from other infected cells when handled simultaneously. Such means of infection are much more likely, as similar problems were shown for mycoplasma contaminations (an incidence of ca. 25% has been reported) and cross contaminations of cell cultures (ca. 15%) [5]. This type of infection with transmissible viruses might be true for the contamination with squirrel monkey retrovirus (SMRV), which was detected in some human and animal cell lines; sequences of the virus were shown to be present in interferon-α preparations produced by the human Burkitt lymphoma cell line NAMALWA [6, 7].

Human and animal cells themselves represent no increased risk during routine cell culture. But an infection of the cells with human pathogenic viruses or bacteria increases the potential risk of a cell culture. Although the probability of the unintentional establishment of a cell line which is infected with a high-risk virus is extremely low, primary cells and cell cultures of unknown origin should be regarded as potentially harmful and are categorized as risk group 2, at least until the infection status of the donor or the cells is clearly determined. Whereas some viruses can be easily propagated in continuous cell lines (e.g., human retroviruses), propagation of other viruses depends on the microenvironment or maturation of the otherwise permissive cells. Additionally, some viruses exhibit a latent or cryptic infection cycle, during which no active viruses are produced (e.g., Epstein-Barr virus (EBV), proviruses of retroviruses). However, the latent status can be switched to the productive lytic cycle by certain inducers, or constantly low replication rates can be found [8].

In this report, we describe the use of polymerase chain reaction (PCR) assays, enzyme-linked immunosorbent assay (ELISA), Southern and Western blotting for the detection of latent and active forms of the human pathogenic viruses (EBV, HBV, HCV, HIV-1, HTLV-I and -II), SMRV, and retroviruses in general in a large panel of continuous primate cell lines to determine the potential risk for handling these cell lines. Regarding EBV, the inducibility of the lytic cycle was investigated by treatment of the latently infected cell lines with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) and sodium butyrate (Na-butyrate).

2. Materials and Methods

2.1. Culture of Cell Lines

The continuous cell lines were provided for accessioning to the cell lines bank by the original or secondary investigators [9]. Cell lines were grown at C in a humidified atmosphere of air containing 5% CO2. The basic growth media (Invitrogen, Karlsruhe, Germany) were supplemented with 10%–20% fetal bovine serum (FBS) (Sigma, Deisenhofen, Germany). For growth factor-dependent cell lines, specific growth factors or conditioned media containing growth factors were added. No antibiotics were added to the cultures. All cell lines were free of mycoplasma and other bacterial, yeast, and fungi contaminations as tested by PCR and microbiological growth assays [10]. The authenticity of the cell lines was determined by DNA typing [11]. For the induction of the lytic cycle of EBV infection, PCR-positive cell lines were treated for 3 days with  M TPA (Sigma) and 3 mM Na-butyrate (Sigma).

2.2. Western Blotting Analysis

A total of  cells were pelleted and washed with ice-cold phosphate buffered saline (PBS), resuspended in 30  L ice-cold protease inhibitor buffer containing 0.1 M NaCl, 10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1  g/mL aprotinin, and 100  g/mL phenylmethylsulfonyl fluoride and boiled for 10 minutes after addition of 30  L 2 SDS gel-loading buffer containing 125 mM Tris-HCl, pH 6.8, 4% SDS, 20% glycerol 2% -mercaptoethanol, and 0.1% bromophenol blue. Proteins were separated on 10% SDS-PAGE. Blotting and staining conditions were as described previously [12]. BZLF1 protein was detected using the mouse anti-ZEBRA antibody (DakoCytomation, Hamburg, Germany) diluted 1 : 100 in PBS and 5% FBS.


Most of the cell lines were analyzed for general infections with retroviruses applying an ELISA. Briefly, using 5 mL cell free culture supernatant, retrovirus particles were concentrated by ultracentrifugation at 100,000   g or by polyethylene glycol precipitation and subsequent centrifugation at 800   g. The pellets were analyzed applying the Reverse Transcriptase Assay, nonradioactive, from Roche (Mannheim, Germany). In this assay, digoxigenin- and biotin-labeled desoxyuridine-triphosphates are incorporated in the presence of viral reverse transcriptase during the synthesis of a DNA strand along a synthetic target of single-stranded DNA molecules. The newly synthesized DNA is trapped on streptavidin-coated microtiter plates and subsequently detected immunologically by binding of peroxidase-labeled antidigoxigenin antibodies and visualized by color development and finally quantified by measuring the absorbance with an ELISA reader [13]. Two different buffers were used to detect Mg2+-dependent RT as well as Mn2+-dependent RT of mammalian C-type retroviruses.

2.4. In Situ Lysing Gel Analysis

Episomal and linear forms of EBV DNA were distinguished by horizontal gel electrophoresis according to Gardella et al. [14]. After electrophoresis, the separated DNA was blotted onto nylon filters (see Southern blot analysis) and the DNA was hybridized with a labeled ca. 37 kb DNA fragment of the -region of EBV (cM-Sal A) [15].

2.5. Southern Blot Analysis

Genomic DNA of cell lines or DNA from EBV was extracted and purified using the PCR High Pure DNA kit from Roche. Fifteen g of genomic DNA or EBV DNA from 24 mL supernatant of the B95-8 cell line were digested with 150 U XhoI restriction enzyme over night. After electrophoresis, the separated DNA was blotted onto a nylon membrane and hybridized with various radioactively labeled cosmid probes from the EBV genome [15] as described earlier [16]. Probes for the - and -region of the linear EBV genome were prepared by PCR. An 894 bp fragment of the -region was amplified using the forward primer F-EBV1 ( -AGG  CAT  TTA  CGG  TTA  GTG  TG- ) and the reverse primer R-EBV1 ( -CGG  TCA  GGA  TAG  CAA  GAA  T- ). PCR was carried out with 35 cycles of 30 seconds at C, 30 seconds at C, and 1 minute at C with hotstart Taq (TaKaRa, Lonza, Verviers, Belgium). A 619 bp fragment of the -region of the linear EBV genome was amplified using the forward primer F-EBV2 ( -ATC  CTC  AGG  GCA  GTG  TGT  CAG- ) and the reverse primer R-EBV2 ( -CAA  GCC  GCA  GCG  ACT  TTC- ). PCR was carried out with 35 cycles of 30 seconds at C, 30 seconds at C, and 1 minute at C with hotstart Taq. The PCR fragments were isolated from the gels and cloned into pGEM-T-easy vectors (Invitrogen). Aliquots of the clear lysates were labeled with by nick translation and hybridized to the Southern blots. Signals were detected with a phosphor imager (Molecular Dynamics, Sunnyvale, CA, USA).

2.6. PCR Assays

PCR or RT-PCR was applied for the detection of specific DNA or RNA sequences of the human pathogenic viruses EBV, HBV, HCV, HHV-8, HIV-1, HTLV-I and -II, and SMRV. DNA sequences integrated into the cellular genome (proviruses) and episomal DNA of EBV and HHV-8 were detected using the PCR amplification method. DNA from cell lines was isolated applying the High Pure PCR Template Preparation kit from Roche. Specific oligonucleotide pairs from the gag region of HIV-1 (SK 38 and SK 39) [17], the pol region of HLTV-I/-II (SK 110 and SK 111) [18], the gag and env region of SMRV (F-SMRV-env, R-SMRV-env and F-SMRV-gag, R-SMRV-gag), from the EB2 (BMLF1) gene of EBV (TC 70 and TC 72) [19], and the putative minor capsid protein gene of HHV-8 (F- and R-HHV-8) [20] were used with the appropriate annealing temperatures in the PCR reaction (Table 1). The hot start PCR was either carried out by denaturing the reaction-mix which contains no Taq-polymerase for 7 minutes at C, subsequently adding the Taq-polymerase mix (1 U/reaction) during the following cycle step at C for 3 minutes, annealing for 2 minutes at the appropriate temperature, and amplification at C for 10 minutes, or by using hotstart Taq-polymerase with initial cycles according to the manufacturer’s recommendations. After the initial cycle, 35 cycles were run at C for 30 seconds, template specific annealing temperature for 30 seconds, and C for 1 minute plus 2 seconds extension for each cycle. The amplified products were identified by agarose gel electrophoresis and visualized by ethidium bromide intercalation.

Annealing temperature:   7 0 C
Reference sequence (mRNA):  GenBank:NM_007313
Reference sequence (genomic DNA):  GenBank:U07563
Nucleotide position (mRNA):  159–374
Nucleotide position (genomic DNA):  49914–50692
RT-PCR product:  216 bp
PCR product:  779 bp
Taq polymerase:  TaKaRa ExTaq HS (Lonza)

Annealing temperature:   6 0 C
Reference sequence:  GenBank: V01555Nucleotide positions: 83520–83784
PCR product (wild type):  265 bpPCR product (internal control): 445 bp
Taq polymerase:  TaKaRa Taq HS (Lonza)

Annealing temperature:   5 5 C
Reference sequence:  GenBank: NC_003977Nucleotide positions: 1874–2436
PCR product (wild type):  563 bpPCR product (internal control):  906 bp
Taq polymerase:BioTherm Taq polymerase (Gene Craft, Lüdinghausen, Germany)

Annealing temperature:   5 5 C
Reference sequence:  GenBank: NC_004102Nucleotide positions: 82–340
PCR product (wild type):  259 bpPCR product (internal control): 452 bp
Taq polymerase:  TaKaRa ExTaq HS (Lonza)

Annealing temperature:   5 6 C
Reference sequence:  GenBank:  NC_009333Nucleotide positions: 47386–47618
PCR product:  232 bp
Taq polymerase:  TaKaRa ExTaq HS (Lonza)

Annealing temperature:   5 0 C
Reference sequence:  GenBank:   NC_001802Nucleotide positions: 1090–1204
PCR product (wild type):  114 bpPCR product (internal control): 403 bp
Taq polymerase:  TaKaRa Taq HS (Lonza)

Annealing temperature:   6 0 C
Reference sequence:  GenBank:  NC_001436Nucleotide positions: 4384–4569
PCR product (wild type):  186 bpPCR product (internal control): 405 bp
Taq polymerase:  TaKaRa Taq HS (Lonza)

Annealing temperature:   6 7 C
Reference sequence:  GenBank:  M23385Nucleotide positions: 6857–7053
PCR product:  197 bp
Taq polymerase:  TaKaRa Ex Taq HS (Lonza)
Annealing temperature:   6 7 C
Reference sequence:  GenBank:  M23385Nucleotide positions: 1737–1922
PCR product:  186 bp
Taq polymerase:  TaKaRa Taq HS (Lonza)

The active form of HBV was tested by organic extraction of DNA from 5 mL supernatant of the cell lines after enrichment of particles by ultracentrifugation (15 minutes at 100,000 g). PCR was carried out using forward and reverse primers from the conserved region of the precore/core protein gene to detect the different subtypes of HBV (Table 1). For the detection of the hepatitis B surface antigen coding region in cell line HEP-3B, a second primer pair was applied, consisting of the forward primer F-HBV-3 ( -CAA  GAT  TCC  TAT  GGG  AGT  GGG  CCT- ) and R-HBV-4 ( -CTC  TGC  CGA  TCC  ATA  CTG  CGG  AAC- ).

For HCV detection, total RNA was isolated from cells by organic extraction with Trizol Reagent (Invitrogen) as described by the manufacturer. Five g were reverse transcribed using random primers and SuperScript reverse transcriptase according to the recommendations of the manufacturer (Invitrogen). The equivalent of 1  g RNA was used for RT-PCR. The amplification was carried applying primers from the untranslated region ( -UTR) of HCV [21] (Table 1).

In all PCR runs appropriate positive, negative, and internal controls were integrated in parallel reactions. As positive control for HIV, a plasmid containing the gag and pol region of HIV-1 was used. This was kindly provided by Dr. H. Hauser (Helmholtz Center for Infection Research, Braunschweig, Germany). As positive control for HTLV, we applied genomic DNA from the human T leukemia cell line MT-1. This cell line is infected with HTLV-I [22]. Regarding EBV and HHV-8, genomic DNA of the cell lines RAJI and CRO-AP2 were used as positive control DNA, respectively [20]. Active HBV reference plasma (subtypes ad and ay) were applied to establish the PCR procedure and used as positive controls. The plasma samples were obtained from the German National Reference Center for Virus Hepatitis (Göttingen, Germany). A plasmid containing the HCV -UTR was kindly provided by Professor Dr. M. Roggendorf from the National Reference Center for Hepatitis C (Essen, Germany).

Except for HHV-8 and SMRV, internal control DNA for each of the PCR assays was constructed starting from the PCR products of the positive control DNA. In general, DNA fragments were cloned into the PCR products to retain the target sequences of the respective primer pairs, but to obtain a PCR product which is significantly longer than the original PCR product of the wild type sequence. For HIV and HTLV, a 250 bp HCV positive control PCR fragment was inserted into the HIV and HTLV fragments, according to the “gene splicing by overlap extension” method described by Telenti et al. [23].

For HBV, the PCR product of the positive control reaction was ligated into the pGEM-T vector and a 445 bp fragment was excised from the insert employing the restriction enzyme BglII. A 788 bp DNA fragment was isolated after digestion of the pGEM vector applying MboI. Both restriction enzymes produce the same sticky end sequences. Thus, the shortened and linearized vector containing the HBV PCR product ends can be ligated with the pGEM restriction fragment, transformed into E. coli, and the resulting plasmid can be used as internal control DNA for HBV. The fragment is 343 bp longer than the wild type sequence. A similar strategy was applied for HCV. The PCR product from the positive control DNA was ligated into the pGEM-T vector and a 187 bp fragment was excised using the restriction enzyme SmaI. pHSSE-1 was digested with RsaI and a 379 bp fragment was extracted from the gel. Blunt-end ligation of the two DNA sequences and transformation into E. coli produced a plasmid containing a DNA sequence which can be amplified with the HCV primer and is 192 bp longer than the wild type DNA.

2.7. Interphase FISH

One million cells were centrifuged at 200   g for 5 minutes. The pellet was washed with 5 mL PBS, centrifuged again at 200   g for 5 minutes, and the cells were resuspended in 0.5 mL PBS. One hundred l of the cell suspension were centrifuged onto acid washed slides using a cytospin centrifuge. The slides were air-dried and the cells were fixed in a mixture of methanol and acetic acid (3 : 1) for 30 minutes in the cold. The fixation step was repeated twice. Then the slides were air-dried for ca. 10 minutes. The samples were dehydrated with an ethanol series (70%, 70%, 90%, 90%, and 100%, each for 2 minutes). The slides were again air-dried for 10 minutes and processed further or stored at C with desiccant.

The EBV cosmid DNA was labeled with Cy3 or Spectrum Green (Vysis, Stuttgart, Germany) by nick-translation (Roche) according to the manufacturer’s protocols. Ca. 40 ng of the labeled probe was added to 1  g of human Cot DNA (Roche) and ethanol precipitated. The pellet was resuspended in 10  l Hybrizol VII (Qbiogene, Heidelberg, Germany), placed on the slide, covered with a cover slip, and sealed with rubber cement. The preparations were denatured at C on a heating plate and the subsequent hybridization was carried out at C over night.

Slides were washed in 2 SSC at room temperature for 1 minute, 3 times in 50% formamide/50% 2 SSC at C for 3 minutes, 3 times in 2 SSC at C for 2 minutes, and 5 minutes at room temperature in 4 SSC. Slides were mounted with Vecta-Shield containing 1  g/mL counterstain 1 (Hoechst, Frankfurt, Germany) and evaluated with a fluorescence microscope.

3. Results and Discussion

3.1. Detection of EBV

EBV became the prime example of a human tumor virus that is etiologically linked to a diverse range of malignancies. EBV has been associated with a variety of lymphoid and epithelial malignancies, such as Burkitt lymphoma, Hodgkin lymphoma, T-cell lymphomas, AIDS-related lymphomas, nasopharyngeal carcinoma, and lymphoepithelioma-like carcinomas of several organs including stomach, salivary glands, thymus, and lung [24]. Additionally, EBV has the unique capability to transform and immortalize resting B cells into permanently growing B-lymphoblastoid cell lines (B-LCL). As EBV is ubiquitously distributed in all human populations and more than 90% of the individuals are infected, the detection of EBV is a priori not a matter of safety. However, for quality control reasons and moreover due to the potential of EBV to transform B cells, cell banks should routinely determine the EBV infection status of cell lines. Not every cell line derived from a tumor patient is necessarily a tumor cell line as nonmalignant cells which are independent of the tumor cells may sometimes be immortalized as well. In a leukemic context, such cell lines are usually normal B-cells which become immortalized through incorporation of the EBV genome. There are several hematopoietic diseases from which it is notoriously difficult to establish cell lines, in particular the mature B-cell malignancies such as chronic lymphocytic leukemia, hairy cell leukemia, plasma cell leukemia (PCL), multiple myeloma, and Hodgkin lymphoma. While there are number of bona fide myeloma-, PCL-, and Hodgkin lymphoma-derived cell lines, various cell lines which are in reality B-LCLs have been described and are still being used as model systems for these diseases. Experimental results from such misclassified cell lines might easily lead to false conclusions regarding the investigated tumor type.

Although the contamination with EBV is not detrimental to the cell culture, the effect of the contamination can be manifold. For example, the gene regulation of the cells can be influenced by transcription factors or altered methylation patterns, and central signal transduction pathways might be activated or inhibited by viral products (e.g., NF- B, interferons) and might alter the physiology of the cells significantly.

We also investigated the presence of EBV infections in nonhematopoietic cell lines to determine whether some of the carcinoma cell lines of the above mentioned tissues might also be linked to EBV infections. In order to inhibit spread of the infections among cell cultures and for the classification of the cell lines into risk groups, it is important to know whether the infection is latent and no active viruses are produced or whether EBV particles are produced during the lytic phase of infection. In some cell lines the lytic phase of EBV infection can be induced, depending on the culture conditions. The possibility of induction of the release of active viruses was investigated by the treatment of the cells with TPA and Na-butyrate, because it is also relevant for the risk group classification of the cell lines.

The general infection status of cell lines with EBV was analyzed by PCR. This method detects linear genomes of the active EBV particles as well as EBV genomes integrated into the eukaryotic chromosomes and nonintegrated EBV episomes. The analyses revealed that 39 out of 465 primate cell lines contain sequences of the EBV genome (see Tables 2 and 3). Figure 1 shows a representative gel after performing EBV-PCR. All PCR positive human cell lines were established from B-lineage leukemia/lymphoma cells, natural killer cells, or are EBV transformed B-lymphoblastoid cells. No cell lines originating from other tissues were found to be . To demonstrate the integrity and the sensitivity of the PCR runs each sample was assayed in duplicate, one reaction without an internal control, and one reaction was spiked with the internal control DNA in a dilution that was close to the detection limit of the PCR assay (Figure 1).

Cell lineCell typePCRaBZLF1 expr.aIn situ lysing gelbSouthern blotcFISHd

B95-8marmoset monkey lymphocytes++++++++++++
BONNA-12hairy cell leukemia+++++++ (h)
CI-1B cell lymphoma++n.d.+
CRO-AP2B cell lymphoma+(+)+++
CRO-AP5B cell lymphoma+(+)+++
DAUDIBurkitt lymphoma++++++++ (h)
DOHH-2B cell lymphoma++ (f)
EB-1Burkitt lymphoma+++++++ (h)
EHEBchronic B cell leukemia++(+)+n.d.
GRANTA-519B cell lymphoma+++++++++
HC-1hairy cell leukemia++++(+)+++++
JIYOYEBurkitt lymphoma++++++++++
JVM-13chronic B cell leukemia+++ (2 bands)+++++
JVM-2chronic B cell leukemia+++++++
JVM-3chronic B cell leukemia+++++++
MEC-1chronic B cell leukemia++++++ (h)
MEC-2chronic B cell leukemia+++++ (h)
NAMALWABurkitt lymphoma+(+)
NAMALWA.CSN/70Burkitt lymphoma+(+)
NAMALWA.IPN/45Burkitt lymphoma+(+)
NAMALWA.KN2Burkitt lymphoma+(+)
NAMALWA.PNTBurkitt lymphoma+(+)
NK-92natural killer lymphoma+++++
OCI-LY-19B cell lymphoma+
RAJIBurkitt lymphoma++++++++++
T2human-human somatic cell hybrid++++n.d.n.d.
TMMB-LCL++ (2 bands)(+)++++
VALB cell lymphoma++++ (2 bands)+n.d.++ (h)
YTT/natural killer cell leukemia++++++++++++

B-LCL: B-lymphoblastoid cell line; expr.: expression; n.d.: not determined; untr.: untreated.
a−: negative; +: positive.
b−: negative; (+): weakly positive; +: positive; ++: strongly positive; +++: very strongly positive.
c −: no bands visible; (+): very weak signals; +: clear bands visible.
d episomal load detected by FISH: −: no episomes; +: low load; ++: load; +++: high load; ++++: very high load; (h): heterogenous distribution of the episomes among the cells; (f): only a few cells containing episomes.


22RV1Prostate cancer
23132/87Gastric adenocarcinoma
293Embryonal kidney
293TEmbryonal kidney
380Pre B cell leukemia
5637Urinary bladder carcinoma
639-VUrinary bladder carcinoma
647-VUrinary bladder carcinoma
697Pre B cell leukemia
8305CThyroid carcinoma
8505CThyroid carcinoma
A-427Lung carcinoma
A-431Epidermoid carcinoma
A-498Kidney carcinoma
A-549Lung carcinoma
AC-1M32Choriocarcinoma-trophoblast hybrid
AC-1M46Choriocarcinoma-trophoblast hybrid
AC-1M59Choriocarcinoma-trophoblast hybrid
AC-1M81Choriocarcinoma-trophoblast hybrid
AC-1M88Choriocarcinoma-trophoblast hybrid
ACH1PChoricarcinoma-trophoblast hybrid
ALL-SILT cell leukemia
AML-193Acute myeloid leukemia
AN3-CAEndometrial adenocarcinoma
AP-1060Acute myeloid leukemia
ARH-77Multiple myeloma+
BC-3CUrinary bladder transitional cell carcinoma
B-CPAPThyroid carcinoma
BD-215B lymphoblastoid cells+
BE-13T cell leukemia
BENLung carcinoma
BEN-MEN-1Benign meningioma
BFTC-905Urinary bladder transitional cell carcinoma
BFTC-909Kidney transitional cell carcinoma
BHT-101Thyroid carcinoma
BHYOral squamous carcinoma
BL-2Burkitt lymphoma
BL-41Burkitt lymphoma
BL-70Burkitt lymphoma
BLUE-1Burkitt lymphoma
BM-1604Prostate carcinoma (derivative of DU-145)
BONNA-12Hairy cell leukemia+
BPH-1Prostate benign hyperplasia
BT-474Breast ductal carcinoma
BT-BCervix carcinoma (subclone of HELA)
BV-173Pre B cell leukemia
C-433Ewing’s sarcoma
CA-46Burkitt lymphoma
CACO-2Colon adenocarcinoma
CADO-ES1Ewing’s sarcoma
CAKI-1Kidney carcinoma
CAKI-2Kidney carcinoma
CAL-120Breast adenocarcinoma
CAL-12TNon-small cell lung carcinoma
CAL-148Breast adenocarcinoma
CAL-27Tongue squamous cell carcinoma
CAL-29Urinary bladder transitional cell carcinoma
CAL-33Tongue squamous cell carcinoma
CAL-39Vulva carcinoma
CAL-51Breast carcinoma
CAL-54Kidney carcinoma
CAL-62Thyroid anaplastic carcinoma
CAL-85-1Breast adenocarcinoma
CAPAN-1Pancreas adenocarcinoma
CAPAN-2Pancreas adenocarcinoma
CCRF-CEMT cell leukemia
CGTH-W-1Thyroid carcinoma
CI-1B cell lymphoma+
CL-11Colon carcinoma
CL-14Colon carcinoma
CL-34Colon carcinoma
CL-40Colon carcinoma
CMKAcute megakaryocytic leukemia
CML-T1T cell leukemia
COLO-206FColon carcinoma
COLO-320Colon adenocarcinoma
COLO-677Small cell lung carcinoma
COLO-678Colon carcinoma
COLO-680NEsophagus squamous cell carcinoma
COLO-699Lung adenocarcinoma
COLO-704Ovary adenocarcinoma
COLO-720LB lymphoblastoid cells+
COLO-824Breast carcinoma
CPC-NSmall cell lung carcinoma
CRO-AP2B cell lymphoma+
CRO-AP3B cell lymphoma
CRO-AP5B cell lymphoma+
CRO-AP6B cell lymphoma
CTV-1T cell leukemia
CX-1Colon adenocarcinoma
DAN-GPancreas carcinoma
DAUDIBurkitt lymphoma+
DBB cell lymphoma
DELMalignant histiocytosis
DERL-2T cell lymphoma
DERL-7T cell lymphoma
DG-75Burkitt lymphoma
DLD-1Colon adenocarcinoma
DM-3Sarcomatoid mesothelioma
DND-41T cell leukemia
DOGKITBurkitt lymphoma
DOGUMBurkitt lymphoma
DOHH-2B cell lymphoma+
DU-145Prostate carcinoma
DU-4475Breast carcinoma
DV-90Lung adenocarcinoma
EB-1Burkitt lymphoma+
ECV-304Urinary bladder carcinoma (derivative of T-24)
EFE-184Endometrium carcinoma
EFM-19Breast carcinoma
EFM-192ABreast carcinoma
EFM-192BBreast carcinoma
EFM-192CBreast carcinoma
EFO-21Ovary cystadenocarcinoma
EFO-27Ovary adenocarcinoma
EGI-1Bile duct carcinoma
EHEBChronic B cell leukemia+
EJMMultiple myeloma
EM-2Chronic myeloid leukemia
EM-3Chronic myeloid leukemia
ENEndometrial carcinoma
EOL-1Eosinophilic leukemia
EPLC-272HLung carcinoma
ESS-1Endometrial stromal sarcoma
EVSA-TBreast carcinoma
F-36PAcute myeloid leukemia
FKH-1Acute myeloid leukemia
FU-OV-1Ovarian cancer
GDM-1Acute myelomonocytic leukemia
GF-D8Acute myeloid leukemia
GIRARDI HEART C2Cervix carcinoma (subclone of HELA)
GIRARDI HEART C7Cervix carcinoma (subclone of HELA)
GRANTA-519B cell lymphoma+
GUMBUSBurkitt lymphoma
H-1184Lung small cell carcinoma
H-1339Lung small cell carcinoma
H-1963Small cell lung carcinoma
H-209Lung small cell carcinoma
H-2171Small cell lung carcinoma
HAL-01B cell precursor leukemia
HC-1Hairy cell leukemia+
HCC-1143Breast carcinoma
HCC-15Non-small cell lung carcinoma
HCC-1599Breast carcinoma
HCC-1937Breast carcinoma
HCC-33Lung small cell carcinoma
HCC-366Lung squamous adenocarcinoma
HCC-44Non-small cell lung carcinoma
HCC-78Non-small cell lung carcinoma
HCC-827Non-small cell lung carcinoma
HCEC-12Cornea endothelium
HCEC-B4G12Cornea endothelium
HCEC-H9C1Cornea endothelium
HCT-116Colon carcinoma
HCT-15Colon adenocarcinoma
HDLM-2Hodgkin lymphoma
HD-MY-ZHodgkin lymphoma
HDQ-P1Breast carcinoma
HELACervix carcinoma
HELA-S3Cervix carcinoma (subclone of HELA)
HEP-3BHepatocellular carcinoma+
HEP-G2Hepatocellular carcinoma
HL-60Acute myeloid leukemia
HMC-1Mast cell leukemia
HNOral squamous carcinoma
HNT-34Acute myeloid leukemia
HPB-ALLT cell leukemia
HSB-2T cell leukemia
HTB cell lymphoma
HT-1376Bladder carcinoma
HT-29Colon adenocarcinoma
HTC-C3Thyroid carcinoma
HUP-T3Pancreas carcinoma
HUP-T4Pancreas carcinoma
IM-9Multiple myeloma+
JEKO-1B cell lymphoma
JIMT-1Breast carcinoma
JIYOYEB cell lymphoma+
JJN-3Plasma cell leukemia
JK-1Chronic myeloid leukemia
JL-1Epitheloid mesothelioma
JMSU-1Urinary bladder carcinoma
JOSK-IHistiocytic lymphoma (derivative of U-937)
JOSK-MHistiocytic lymphoma (derivative of U-937)
JURKATT cell leukemia
JURL-MK1Chronic myeloid leukemia in blast crisis
JURL-MK2Chronic myeloid leukemia in blast crisis
JVM-13Chronic B cell leukemia+
JVM-2Chronic B cell leukemia+
JVM-3Chronic B cell leukemia+
K-562Chronic myeloid leukemia
KARPAS-1106PB cell lymphoma
KARPAS-231B cell leukemia
KARPAS-299T cell lymphoma
KARPAS-422B cell lymphoma
KARPAS-45T cell leukemia
KARPAS-620Plasma cell leukemia
KASUMI-1Acute myeloid leukemia+
KASUMI-2B cell precursor leukemia
KBCervix carcinoma (subclone of HELA)
KB-3-1Cervix carcinoma (subclone of HELA)
KB-V1Cervix carcinoma (subclone of HELA)
KCI-MOH1Pancreatic adenocarcinoma
KCL-22Chronic myeloid leukemia in blast crisis
KE-37T cell leukemia
KG-1Acute myeloid leukemia
KG-1aAcute myeloid leukemia
KM-H2Hodgkin lymphoma
KMOE-2Acute erythremia
KMS-12-PEMultiple myeloma
KOPN-8B cell precursor leukemia
KPL-1Breast carcinoma
KU-19-19Urinary bladder carcinoma
KU-812Chronic myeloid leukemia in myeloid blast crisis
KYO-1Chronic myeloid leukemia in blast crisis
KYSE-140Esophageal carcinoma
KYSE-150Esophageal carcinoma
KYSE-180Esophageal carcinoma
KYSE-270Esophageal carcinoma
KYSE-30Esophageal carcinoma
KYSE-410Esophageal carcinoma
KYSE-450Esophageal carcinoma
KYSE-510Esophageal carcinoma
KYSE-520Esophageal carcinoma
KYSE-70Esophageal carcinoma
L-1236Hodgkin lymphoma
L-363Plasma cell leukemia
L-428Hodgkin lymphoma
L-540Hodgkin lymphoma
L-591B lymphoblastoid cells+
L-82Anaplastic large cell lymphoma
LAMA-84Chronic myeloid leukemia
LAMA-87Chronic myeloid leukemia in blast crisis
LCLC-103HLung carcinoma
LCLC-97TM1Lung carcinoma
LCL-HOB lymphoblastoid cells++
LCL-WEIB lymphoblastoid cells+
LNCAPProstata carcinoma
LOUCYT cell leukemia
LOU-NH91Lung carcinoma
LOVOColon adenocarcinoma
LP-1Multiple myeloma
LXF-289Lung adenocarcinoma
M-07eAcute megakaryoblastic leukemia
MB-1Anaplastic thyroid carcinoma
MC-116B cell lymphoma
MCF-7Breast adenocarcinoma
MDA-MB-453Breast carcinoma
ME-1Acute myeloid leukemia
MEC-1Chronik B cell leukemia+
MEC-2Chronic B cell leukemia+
MEG-01chronic myeloid leukemia in megakaryocytic blast crisis
MFE-280Endometrium carcinoma
MFE-296Endometrium carcinoma
MFE-319Endometrium carcinoma
MFM-223Breast carcinoma
MHH-CALL-2B cell precursor leukemia
MHH-CALL-3B cell precursor leukemia
MHH-CALL-4B cell precursor leukemia
MHH-ES-1Ewing’s osteosarcoma
MHH-PREB-1B cell lymphoma
MKN-45Gastric carcinoma
ML-1Follicular thyroid carcinoma
ML-2Acute myelomonocytic leukemia
MN-60B cell lymphoma
MOLM-13Acute myeloid leukemia
MOLM-16Acute myeloid leukemia
MOLM-20Chronic myeloid leukemia
MOLM-6Chronic myeloid leukemia in blast crisis
MOLP-2Multiple myeloma
MOLP-8Multiple myeloma
MOLT-13T cell leukemia
MOLT-14T cell leukemia
MOLT-16T cell leukemia
MOLT-17T cell leukemia
MOLT-3T cell leukemia
MOLT-4T cell leukemia
MONO-MAC-1Acute monocytic Leukemia
MONO-MAC-6Acute monocytic leukemia
MOTN-1T cell leukemia
MSTO-211HLung carcinoma
MT-3Breast carcinoma
MUTZ-2Acute myeloid leukemia
MUTZ-3Acute myelomonocytic leukemia
MUTZ-5B cell precursor leukemia
MV4-11Acute monocytic leukemia
NALM-1Chronic myeloid leukemia in blast crisis
NALM-19B cell precursor leukemia
NALM-6B cell precursor leukemia
NAMALWABurkitt lymphoma++
NAMALWA.CSN/70Burkitt lymphoma++
NAMALWA.IPN/45Burkitt lymphoma++
NAMALWA.KN2Burkitt lymphoma++
NAMALWA.PNTBurkitt lymphoma++
NB-4Acute promyelocytic leukemia
NCI-H510ASmall cell extra-pulmonary carcinoma
NCI-H82Small cell lung carcinoma
NCI-H929Multiple myeloma
NC-NCB-lymphoblastoid cells+
NK-92Natural killer cell lymphoma+
NOMO-1Acute myeloid leukemia
NTERA-2human embryonal carcinoma (teratocarcinoma)
NU-DHL-1B cell lymphoma
NU-DUL-1B cell lymphoma
OCI-AML2Acute myeloid leukemia
OCI-AML3Acute myeloid leukemia
OCI-AML5Acute myeloid leukemia
OCI-LY-19B cell lymphoma+
OCI-M1Acute myeloid leukemia
OCI-M2Acute myeloid leukemia
ONCO-DG-1Papillary thyroid carcinoma
OPM-2Multiple myeloma
P12-ICHIKAWAT cell leukemia
PA-TU-8902Pancreas adenocarcinoma
PA-TU-8988SPancreas adenocarcinoma
PA-TU-8988TPancreas adenocarcinoma
PC-3Prostate carcinoma
PEERT cell leukemia
PF-382T cell leukemia
PL-21Acute myeloid leukemia
PLB-985Acute myeloid leukemia
RAJIBurkitt lymphoma+
RAMOSBurkitt lymphoma
RCH-ACVB cell precursor leukemia
RC-K8B cell lymphoma
RD-ESEwing’s osteosarcoma
REC-1B cell lymphoma
REHPre B cell leukemia
RI-1B cell lymphoma
RLB cell lymphoma
ROB lymphoblastoid cell line+
ROS-50B cell leukemia
RPMI-2650Nasal septum squamous carcinoma
RPMI-8226Multiple myeloma
RPMI-8402T cell acute lymphoblastic leukemia
RS4;11B cell precursor leukemia
RS-5Sacromatoid mesothelioma
RT-112Urinary bladder carcinoma
RT-4Urinary bladder carcinoma
S-117Thyroid sarcoma
SAOS-2Osteogenic carcinoma
SBC-2Cervix carcinoma (subclone of HELA)
SBC-7Cervix carcinoma (subclone of HELA)
SC-1B cell lymphoma
SCC-25Squamous cell carcinoma
SCC-4Squamous cell carcinoma
SCLC-21HSmall cell lung carcinoma
SCLC-22HSmall cell lung carcinoma
SD-1B lymphoblastoid cells+
SEMB cell precursor leukemia
SET-2Essential thromobocythemia
SH-2Acute myeloid leukemia
SHI-1Acute myeloid leukemia
SIG-M5Acute monocytic leukemia
SISOCervix carcinoma
SK-ES-1Ewing’s sarcoma
SK-HEP-1Liver adenocarcinoma
SKM-1Acute myeloid leukemia
SK-MES-1Squamous lung carcinoma
SK-MM-2Multiple Myeloma
SKW-3T cell leukemia
SPI-801Chronic myeloid leukemia (K-562 subclone)
SPI-802Chronic myeloid leukemia (K-562 subclone)
SR-786Anaplastic large T cell lymphoma
SU-DHL-1Anaplastic large cell lymphoma
SU-DHL-10B cell lymphoma
SU-DHL-16B cell lymphoma
SU-DHL-4B cell lymphoma
SU-DHL-5B cell lymphoma
SU-DHL-6B cell lymphoma
SU-DHL-8B cell lymphoma
SUP-B15B cell precursor leukemia
SUP-HD1Hodgkin lymphoma
SUP-M2Anaplastic large cell lymphoma
SUP-T1T cell lymphoma
SUP-T11T cell leukemia
SW-1710Urinary bladder carcinoma
SW-403Colon adenocarcinoma
SW-480Colon adenocarcinoma
SW-948Colon adenocarcinoma
T2Human-human somatic cell hybrid+
T-24Bladder carcinoma
TALL-1T cell leukemia
TANOUEB cell precursor leukemia
TC-71Ewing’s sarcoma
TCC-SUPBladder carcinoma
TFK-1Bile duct carcinoma
THP-1Acute monocytic leukemia
TMMChronic myeloid leukemia+
TOM-1B cell precursor leukemia
TT2609-C02Follicular thyroid carcinoma
U-2197Malignant fibrous histiosarcoma
U-2932B cell lymphoma
U-2940B cell lymphoma
U-2973B cell lymphoma
U-698-MB cell lymphoma
U-937Hystiocytic lymphoma
U-H01Hodgkin lymphoma
ULAB cell lymphoma
UT-7Acute myeloid leukemia
VA-ES-BJEpithelioid sarcoma
VALB cell l+
VM-CUB1Bladder carcinoma
WSU-DLCL2B cell lymphoma
WSU-FSCCLB cell lymphoma
WSU-NHLB cell lymphoma
YAPCPancreatic carcinoma
YTT cell/natural killer cell leukemia+

*: Monkey cell lines; − : negative; + (bold): positive.

A number of cell lines were examined for EBV infection by the originators of the cell lines or later on by other investigators. In the majority of cases the EBV status of the cell lines was determined immunologically by the detection of EBV nuclear antigen (EBNA), early antigen (EA), and/or viral capsid antigen (VCA). Concordance of our PCR results with data for protein expression given in the literature was found in nine cell lines (ARH-77, BONNA-1, HC-1, JIYOYE, L-591, MEC-1, MEC-2, RAJI, and YT) [9, 25, 26]. The DOHH-2 cell line was originally described as EBV negative but was later on found to be EBV positive in EBNA immunofluorescence staining and PCR [27, 28]. In three cell lines (CRO-AP2, CRO-AP5, and HC-1) EBV sequences were demonstrated by Southern blotting [2931] and four cell lines were described to be established by immortalization with EBV particles from supernatant of the B95-8 cell line (EHEB, JVM-13, JVM-2, and JVM-3) [32, 33]. The monkey cell line B95-8 is known to produce infectious EBV particles [34]. In contrast to our PCR results, the cell lines CI-1, NK-92, and TMM were specified as EBV negative as examined by EBNA and PCR assays [3537]. Our PCR results were verified by FISH, in situ lysing gel analysis, Southern and Western blotting as described below and showed in at least two additional assays that all those cell lines are clearly EBV-positive (see Table 2).

The CI-1, DOHH-2, and TMM cell lines were positive in our PCR assay but showed weak or few signals in in situ lysing gel analysis and FISH (see below). This indicates that the EBV load of the cells is very low and that the expression of EBNA protein in these three cell lines was below the detection limit of the immunological assays. Thus, PCR is a convenient and reliable assay to detect EBV infections in cell cultures, provided that the appropriate control reactions including internal DNA controls are performed to avoid false positive and false negative results.

The activation of the lytic phase of the virus is usually closely connected with the production of infectious virus particles in the cells. The permissivity of a cell line relating to EBV is important to determine legally the risk group of the cell line as only cell cultures producing active viruses should represent an elevated risk. To identify the lytic phase of the EBV infections, we analyzed the expression of the ZEBRA protein (Bam HI Z Epstein-Barr replication activator) [38] by Western blotting applying an anti-ZEBRA monoclonal antibody. ZEBRA is the product of the BZLF1 gene and is a transcriptional activator that mediates a genetic switch between the latent and lytic states of EBV. ZEBRA binds to the promoters of genes involved in lytic DNA replication activating their transcription [39]. Thus, phorbol esters and Na-butyrate are among the most reproducible and most broadly applicable inducers of the lytic cycle of EBV [8]. However, not all latently infected lymphoblast cell lines can be induced by TPA and only a minority of the cells within a culture is inducible at all. In some human B-LCL about 10% of the cells can be induced to permit lytic virus replication, whereas in a few others 20%–50% induced cells can be found [8]. Marmoset lymphoblasts seem to be more inducible, for example, the B95-8 cell line [40]. For this reason we used the B95-8 cell line as positive control to determine the efficiency of the induction with TPA/Na-butyrate.

All EBV PCR+ cell lines were incubated with and without  M TPA for 3 days and analyzed for ZEBRA expression. As shown in Table 2, five unstimulated cell lines exhibited a ZEBRA specific band of approximately 40 kDa (B95-8, BD-215, L-591, NC-NC, and YT). The expression of the protein was weak in all five cell lines but increased after TPA/Na-butyrate stimulation. B95-8 and BD-215 increased strongly, whereas L-591 and YT increased only moderately. Six additional cell lines which showed no expression in the absence of TPA/Na-butyrate produced the ZEBRA protein in various amounts after induction of the lytic phase with TPA (EB-1, GRANTA-519, HC-1, IM-9, JIYOYE, and VAL). All other cell lines tested ( ) did not express the BZLF1 gene product even after stimulation with TPA/Na-butyrate. Figure 2 shows a representative Western blot with positive and negative cell lines. Lieberman et al. [41] showed that the ZEBRA protein is induced by TPA in RAJI cells. This was not confirmed in our screening for ZEBRA expression. RAJI is a nonproducer cell line with at least two deletions in the EBV genome and is defective for EBV DNA replication and late gene expression [8]. On the other hand, Di Francesco et al. [42] showed a weak induction of ZEBRA in Western blots after treatment with TPA in combination with n-butyrate, whereas further addition of cocain caused a high increase in ZEBRA expression. These contradictory findings can be explained by different cell sources or cell passage histories. However, importantly all studies demonstrated that ZEBRA was not expressed during normal cell culture, and thus, a production of viruses is very unlikely at nonstimulating conditions.

The EBV genome can be present in the host cells as covalently closed circles (episomes), as linear DNA of active viruses, or integrated into the host genome. The episomes are indicative for the latent infection status [8]. The EBV infected cells can harbor 1–10 episomes in low load cells or up to several hundred episomes in high load cells. EBV producer cell lines contain also linear double stranded DNA which is packaged into the virions. EBV genome integration was described only for a small number of cell lines. For example, the NAMALWA cell line and its subclones are described to contain an integrated EBV genome [43] and no episomes, whereas the RAJI cell line was reported to contain both, chromosomally integrated EBV genomes as well as episomes [44]. To distinguish between the linear DNA of active viruses, episomal DNA of EBV-infected cell cultures, and solely integrated EBV genomes, we performed a variation of a Southern blot analysis as described by Gardella et al. [14].

The autoradiograms showed the episomal DNA as clear-cut bands whereas the linear DNA usually formed distinct bands within a smear of DNA (Figure 3). The episomal as well as the linear DNA of the cell lines examined showed different migrations indicating different EBV clones. Except for the NAWALWA cell line and its subclones, DOHH-2, and OCI-LY19, all EBV PCR positive cell lines showed at least one band of episomal EBV genomes (Table 2). As no denaturing conditions were applied in the in situ lysing gels, different sequences of the EBV strains can result in different conformations and mobilities of the episomes. The cell lines COLO-720L, IM-9, JVM-13, LCL-HO, TMM, and VAL displayed two episomal DNA bands. The intensities of the episomal bands were almost identical only in the cell line JVM-13. The existence of two EBV clones in one cell line can be explained by three assumptions: (i) two different EBV clones simultaneously infected the cell which led to the establishment of the cell line, (ii) the cell line was established from two or more different cells of the patient harboring different EBV clones (oligoclonality), or (iii) single and duplicated episomes are present in the nuclei of the cell lines.

The NK-92 and TMM cell lines were described to be EBV negative according to EBNA detection assay and PCR, respectively [35, 37]. Both cell lines showed EBV specific episomal DNA in the in situ lysing gels. This confirmed the results of the PCR assay as discussed above. Concerning the NAMALWA cell lines, no episomal DNA bands were expected, because the EBV DNA was described to be integrated into the eukaryotic genome [45]. Since no linear DNA was detected, the integrated genome is not transcribed in those cell lines. DOHH-2 and OCI-LY-19 might also only contain integrated EBV genomes, but fluorescence in situ hybridization (FISH) indicates that the number of EBV episomes in a cell culture is too low to be detected by in situ lysing gels (see below).

The intensities of the episomal bands in the in situ lysing gels were highly variable among the cell lines but were constant for a given cell line, indicating that the EBV loads are different in the cell lines examined. The highest episomal loads were found in the cell lines DAUDI, IM-9, L-591, RAJI, and SD-1. Of these, only the L-591 cell line expressed BZLF1 constitutively and IM-9 expressed the protein after stimulation with TPA and Na-butyrate. The other BZLF1 expressing cell lines displayed a lower number of episomes. This indicates that the lytic cycle induction is completely indepentent from the number of episomes present in the nuclei. High episomal loads were described for the cell line DAUDI and RAJI, which carry 100–200 and 50–60 viral copies per cell, respectively [23, 46]. Based on the intensities of the EBV-specific bands in the autoradiograms of the in situ lysing gel assays, the numbers of episomes in IM-9 and SD-1 were comparable to those of DAUDI or RAJI, respectively. All other cell lines were low load cell lines with 1–10 EBV copies per cell compared to the high load cell lines mentioned above (Figure 3).

In order to obtain more quantitative data on the EBV load of the cell lines, we performed single cell analyses by interphase FISH. The analysis showed that the viral load of the nonproducing cells within a culture was heterogeneous. Some cells had high EBV loads, whereas other cells of the same cell culture showed low or even no viral load. For example, the cell line DOHH-2 contains only a few cells with several EBV episomes, whereas in most of the cells EBV DNA was completely absent (Figure 4(b)). Any cross-contamination of the cell line was excluded by DNA typing (data not shown). The heterogeneity of EBV load within a cell culture population and the finding that only a small fraction of cells can be stimulated to enter the lytic phase implies that specific cellular factors regulate the propagation of episomes in the nuclei and the permissivity of the cells related to EBV. Phosphorylation or methylation of EBV specific proteins or epigenetic events like DNA methylation or histone deacetylation might contribute to the cell specific regulation [39].

Linear EBV DNA was detected in a number of cell lines (Table 2). The expression of linear EBV genome DNA did not correspond to the expression of BZLF1 protein. Although all BZLF1 positive cell lines produced high levels of linear EBV DNA, many more BZLF1 negative cell lines also expressed significant levels of linear EBV genomes. This indicates that the lytic status of the EBV infection is not essential for the production of linear EBV genomes. The intensities of the linear EBV DNA bands did not correlate to the intensities of the episomes. For example, the cell line IM-9 displayed a very strong episomal DNA signal, whereas no linear DNA was detectable in untreated cells and very low amounts were seen in TPA/Na-butyrate treated cells (Figure 5). On the other hand, cell line YT showed a strong band for linear DNA, but a weak band for the episomal DNA. The number of episomes per cell was not affected by the stimulation with TPA/Na-butyrate, whereas the amount of linear DNA increased with the addition of TPA in those cell lines which can be stimulated with the phorbol ester.

Cross-contamination is a serious problem in cell culture and causes mycoplasma infection and cell line cross-contamination. To find out whether a transfer of EBV from one cell culture to another can be demonstrated, we investigated the clonality of the EBV genomes. We performed Southern blot analysis with genomic DNA of the EBV-PCR positive cell lines digested with the restriction enzyme XhoI. Applying EBV cosmids covering almost the whole EBV genome [15] each cell line displayed a unique EBV genotype. The most striking differences occurred in the lengths of the terminal repeat (TR) regions which reflect the numbers of repetitive exons. The other parts of the genome covered by the cosmids (ca. 83% of the B95-8 EBV sequence) showed also a high variability. Several different patterns can be identified per cosmid probe and the combination of several cosmid probes revealed a high number of different genotypes (Figure 6). Even the cell lines which were described to be established with EBV particles of the B95-8 cell line displayed differences in the lenght of the TR regions of the EBV genotypes. The JVM cell lines were all established using EBV and TPA [32]. Nevertheless, the cell lines display different patterns concerning the TR region and a few additional bands within the EBV genome. The EHEB cell line was also described to be transformed by B95-8 EBV viruses [9]. The EHEB cell line displays distinct bands in the XhoI-digested EBV DNA different from those found in the JVM cell lines. Nevertheless, the bands of the B95-8 EBV-transformed cell lines detected in the Southern blots are all more or less prominently represented within the pattern of the B95-8 cell line. From these results, we conclude that the B95-8 cell line harbors different genotypes of EBV with the ability to transform other cells.

Taken together, the various patterns of digested EBV indicate that the infections with EB viruses originated from the patient or from the transforming viruses, but not from dissemination during cell culturing. Although mycoplasma and cross contaminants are mainly introduced into cell cultures by inadequate cell culture techniques, this does not seem to be the case with regard to the distribution of EBV in cell cultures. The low number of unintended intercell line contamination by EBV might be based on the low number of cell lines which produce actively EBV. Additionally, only a limited number of cell lines are susceptible to the infection with EBV at all.

3.2. Detection of HBV

HBV particles contain a circular, partially double-stranded DNA of 3.2 kb. HBV can be grown in primary cell cultures of normal adult or fetal human hepatocytes, but propagation was not yet shown in untreated continuous cell lines. Production of HBV particles can be achieved to date only by transfection of hepatocyte cell lines with plasmids containing HBV genomes [47]. In cell lines, the HBV genome is integrated into the eukaryotic chromosomes with variable copy numbers as shown for several cell lines, for example, HCCM, HEP-3B, HUH-1, HUH-4, and PLC/PRF/5 [48]. Except for HCCM, all these cell lines express the hepatitis B surface antigen HBsAg.

The HBV PCR assay used here amplified conserved sequences of the core region of HBV and was evaluated using HBV reference plasma No 1 (subtype ad) and No 2 (subtype ay) which were established in cooperation with the European Study Group on Viral Hepatitis (EUROHEP). In order to determine the detection limit, we performed a dilution series of the HBV particles in conditioned cell culture supernatant of an HBV negative cell line. Subsequently, the HBV particles were recollected by ultracentrifugation, DNA was extracted, and the PCR reaction was performed as described in the methods section. The sensitivity was determined as ca. 50 particles per PCR reaction. This corresponds to ca. 250 HBV particles per mL cell culture supernatant (data not shown).

We screened 465 primate cell lines (Table 3) by performing PCR assays for the detection of active HBV with DNA extractions of the cell culture supernatants and found no cell lines. The HEP-3B cell line was described to carry the HBV genome integrated into the eukaryotic chromosomes [49], but the PCR method we applied detected the contamination neither in the supernatant nor using genomic DNA of the cell line. Su et al. [49] investigated the HBV genome and the integration site within the eukaryotic genome. They determined a ca. 2.3 kb fragment originating from HBV in the HEP-3B cell line and the integration was associated with a chromosomal translocation of the chromosomes 4 and 13. The HBV core region is deleted in the HEP-3B cell line and was thus not detected by the PCR analysis. We confirmed the presence of the HBV fragment in the HEP-3B cell line by Southern blot analysis (Figure 7) on genomic DNA and by PCR amplification of the coding region of the HBsAg.

In HEP-G2 and SK-HEP-1, a hepatocellular carcinoma, and a liver adenocarcinoma cell line, respectively, we did not detect HBV sequences by PCR or Southern blot analysis. Both cell lines are not contaminated with HBV.

3.3. Detection of HCV

HCV infections are widely distributed all over the world and are associated with chronic hepatitis. Until its identification in 1988, the virus was the predominant causative of transfusion-associated hepatitis. Similarly to HBV, until now HCV cannot be propagated in unmanipulated continuous human cell lines.

HCV is a 9.6 kb linear positive-stranded RNA virus and can be detected by reverse transcriptase PCR (RT-PCR). The -UTR is the most conserved part of the virus genome and commonly used for the amplification by RT-PCR. We extracted total RNA from the cell lines and the integrity of the RNA was evaluated by demonstration of the rRNA bands on an ethidium bromide stained gel. The subsequent RT reaction was verified by a PCR reaction amplifying the ubiquitously expressed ABL transcript. This PCR allows (i) to demonstrate the sensitivity of the RT-PCR, because ABL is only moderately transcribed in human cells, and (ii) to distinguish between the cDNA and residual genomic DNA, because the primers are located in two different exons of the ABL gene. Due to the lack of availability of HCV positive cell lines, we used a plasmid containing the -UTR of HCV as positive control and produced an internal control DNA to verify each PCR reaction. The sensitivity of the assay was determined as 10–100 copies per PCR reaction.

We investigated 465 cell lines (Table 3) applying RT-PCR for the conserved -UTR of the HCV genome. None of the cell lines were positive for HCV. This result supports the observation that HCV cannot be propagated in human or other primate cell lines.

3.4. Detection of HIV-1 and HTLV-I and -II

The retroviruses HIV-1 and HTLV-I and II infect human T cells and are involved in the development of AIDS and the adult T-cell leukemia, respectively. The retroviruses contain two RNA molecules which are reverse transcribed into DNA and integrated as proviruses into the host genome. HIV and HTLV can be propagated in continuous cell lines and a number of cell lines were described as being latently infected or actively producing viruses.

PCR assays were established to detect latent infections in terms of proviruses of HIV-1 and HTLV-I and -II in the cell lines. The sensitivity of the PCR assays was determined as about 20 copies per reaction. DNA of the MT-1 cell line was used as positive control for the HTLV-PCR and a plasmid containing the HIV-1 gag and pol regions as positive control for HIV-1.

In total 465 primate cell lines of the cell bank (Table 3) were analyzed by PCR for the presence of those retroviruses and none of the cell lines were found to be infected with HIV or HTLV sequences. Furthermore, 293 of these cell lines were tested for the activity of RT. Only the cell line KASUMI-1 was found to be positive. The activity of 5 mL conditioned KASUMI-1 cell culture supernatant showed an RT activity that was equivalent to approximately 2 ng of HIV-1 RT (specific activity 5 U/ g). For comparison, 5 mL supernatant of the ovine cell line FLK-BLV, which is infected with the bovine leukemia virus, shows an activity equivalent to ca. 10 ng of HIV-1 RT. The cause of the RT activity could not be determined. But PCR analyses excluded the presence of HIV-1, HTLV-I/-II, and SMRV.

3.5. Detection of SMRV

SMRV was first isolated from the lung cell culture of a squirrel monkey after cocultivation with other cell cultures [50]. The endogenous virus belongs to the beta-retroviruses and exhibits Mg-dependent RT. SMRV is not pathogenic to its natural host and pathogenicity was not described for human or other species. The xenotropic virus was shown to be expressed in different cell lines of canine, man, chimpanze, rhesus monkey, and mink origin. Natural or alternate hosts other than squirrel monkey were not yet identified.

Already in 1974 retroviral particles were detected in the human hematopoietic cell line RPMI-8226 which were later identified as SMRV [6, 51]. Oda et al. reported the detection of retroviruses in the human lymphoblastoid cell line HLB which turned out to be SMRV [52, 53]. Middleton et al. reported the insertion of SMRV sequences in the genome of the human Burkitt lymphoma cell line Namalwa [54]. The subclone Namalwa.IPN/45 contains two partial SMRV copies integrated into the cMYC gene locus and 10 further copies integrated at different sites of the genome of the cell line. They also found SMRV sequences in the EBV producing monkey cell line B95-8 and demonstrated that SMRV was transmitted when EBV particles from the B95-8 cell line were used to establish a B lymphoblastoid cell line. SMRV sequences were also detected in interferon- preparations which were produced using the Namalwa cell line [55]. Retroviruses generally insert themselves into the genome of the host cell. As seen in the cell line Namalwa, the insertion can affect not only the transcription activity of cellular oncogenes but also tumor suppressor genes or other regulatory genes. Beside the possibility of altering the cellular characteristics, this leads also to a certain, at least theoretically, possible pathogenicity of retrovirus infections per se; hence the release of those viruses—especially with a very broad host cell spectrum such as xenotropic SMRV—should be minimized. Moreover, a potential risk occurs when cells infected with retroviruses are subjected to retroviral-mediated gene transfer. A recombination of the replication deficient retrovirus and the wild type retroviral genetic information might lead to a complementation of the replication defect and to replication-competent retroviruses [56].

We investigated 430 human and 4 monkey cell lines (Table 3) for the occurrence of SMRV DNA sequences in the genome. Six cell lines were found to be positive for SMRV: five Namalwa subclones (Namalwa, Namalwa.CSN/70, Namalwa.IPN/45, Namalwa.KN2, Namalwa.PNT) and the human lymphoblastoid cell line LCL-HO. Middleton et al. investigated Namalwa cell lines from different laboratories and found no SMRV-free Nalmalwa cell cultures [54]. Our subclones were received from two different laboratories in Japan and Scotland. Presumably, all NAMALWA cell lines are contaminated with SMRV and no SMRV-free cell line is available. The LCL-HO cell line is a lymphoblastoid cell line which was established by transformation of a patients primary B cells with EBV. We suspect that SMRV was transmitted by the use of EBV from an SMRV infected B95-8 cell line. Other LCLs which were transformed with EBV from B95-8 showed no SMRV contamination. This indicates that only some of the B95-8 subclones contain SMRV.

The cell lines were received from different sources worldwide. The low infection rate of the cell lines indicates that SMRV is not transmitted to other cell cultures comparable to the distribution of mycoplasma or cell line cross contaminations, although many different cell types were shown to be susceptible to an infection. Nevertheless, the transmission of these xenotropic viruses during cultivation and handling of infected cell cultures to other cell lines cannot be excluded.

4. Conclusions

In summary, we showed that human and other primate cell lines directly obtained from a biological resource center do not carry high-risk viral contaminants and thus do not represent safety risks for cell culturists. The PCR assays provide a robust, fast, inexpensive, sensitive, and reliable method for routine screening. The additional feature of incorporating an internal control in each assay reduces the possibility of false-negative data. Importantly, unlike mycoplasma and other bacterial infections and cell line cross contamination, viruses are not disseminated among cell lines due to poor cell culture technique. Only a minor part of the cell lines produces active viruses or can be stimulated to produce them. Detection of BZLF1 protein by Western blot, TR sequences by Southern blot, and interphase FISH can be applied to recognize cell lines producing active EBV particles and to assign a cell culture to a legal risk group. Newly established cell lines should be tested for EBV-infections to detect EBV-transformed B-cells giving rise to B-LCLs. On the other hand, the use of EBV from an SMRV+ B95-8 cell line to establish B-LCLs might carry the risk of coinfecting the reccipient cells with SMRV.


The authors thank Dr. Roderick A.F. MacLeod and Maren Kaufmann for technical support on the FISH analyses and Anne Leena Koelz for performing SMRV assays on nonhuman primate cell lines.


  1. A. C. E. Moor, T. M. Dubbelman, J. VanSteveninck, and A. Brand, “Transfusion-transmitted diseases: risks, prevention and perspectives,” European Journal of Haematology, vol. 62, no. 1, pp. 1–18, 1999. View at: Google Scholar
  2. H. Zur Hausen, “Viruses in human cancers,” European Journal of Cancer, vol. 35, no. 14, pp. 1878–1885, 1999. View at: Publisher Site | Google Scholar
  3. A. Farrugia, “Evolving perspectives in product safety for haemophilia,” Haemophilia, vol. 8, no. 3, pp. 236–243, 2002. View at: Publisher Site | Google Scholar
  4. P. A. Lazo, “Structure, DNaseI hypersensitivity and expression of integrated papilloma virus in the genome of HeLa cells,” European Journal of Biochemistry, vol. 165, no. 2, pp. 393–401, 1987. View at: Google Scholar
  5. H. G. Drexler, C. C. Uphoff, W. G. Dirks, and R. A. F. MacLeod, “Mix-ups and mycoplasma: the enemies within,” Leukemia Research, vol. 26, no. 4, pp. 329–333, 2002. View at: Publisher Site | Google Scholar
  6. M. Popovic, V. S. Kalyanaraman, M. S. Reitz, and M. G. Sarngadharan, “Identification of the RPMI 8226 retrovirus and its dissemination as a significant contaminant of some widely used human and marmoset cell lines,” International Journal of Cancer, vol. 30, no. 1, pp. 93–99, 1982. View at: Google Scholar
  7. M. Pienkowska and A. Seth, “Detection of squirrel monkey retroviral sequences in interferon samples,” Journal of Hepatology, vol. 28, no. 3, pp. 396–403, 1998. View at: Publisher Site | Google Scholar
  8. E. Kieff and A. B. Rickinson, “Epstein-Barr virus and its replication,” in Fields Virology, B. N. Fields, D. M. Knipe, and P. M. Howley, Eds., pp. 2603–2654, Lippincott-Williams and Wilkins, Philadelphia, Pa, USA, 5th edition, 2007. View at: Google Scholar
  9. H. G. Drexler, W. Dirks, R. A. F. MacLeod, H. Quentmeier, K. G. Steube, and C. C. Uphoff, “DSMZ catalogue of human and animal cell lines,” 2008, View at: Google Scholar
  10. C. C. Uphoff and H. G. Drexler, “Comparative PCR analysis for detection of mycoplasma infections in continuous cell lines,” In Vitro Cellular and Developmental Biology: Animal, vol. 38, no. 2, pp. 79–85, 2002. View at: Google Scholar
  11. W. G. Dirks, S. Faehnrich, I. A. J. Estella, and H. G. Drexler, “Short tandem repeat DNA typing provides an international reference standard for authentication of human cell lines,” Altex, vol. 22, no. 2, pp. 103–109, 2005. View at: Google Scholar
  12. H. Quentmeier, W. G. Dirks, R. A. F. Macleod, J. Reinhardt, M. Zaborski, and H. G. Drexler, “Expression of HOX genes in acute leukemia cell lines with and without MLL translocations,” Leukemia and Lymphoma, vol. 45, no. 3, pp. 567–574, 2004. View at: Publisher Site | Google Scholar
  13. J. Eberle and R. Seibl, “A new method for measuring reverse transcriptase activity by ELISA,” Journal of Virological Methods, vol. 40, no. 3, pp. 347–356, 1992. View at: Publisher Site | Google Scholar
  14. T. Gardella, P. Medveczky, T. Sairenji, and C. Mulder, “Detection of circular and linear herpesvirus DNA molecules in mammalian cells by gel electrophoresis,” Journal of Virology, vol. 50, no. 1, pp. 248–254, 1984. View at: Google Scholar
  15. A. Polack, G. Hartl, and U. Zimber, “A complete set of overlapping cosmid clones of M-ABA virus derived from nasopharyngeal carcinoma and its similarity to other Epstein-Barr virus isolates,” Gene, vol. 27, no. 3, pp. 279–288, 1984. View at: Publisher Site | Google Scholar
  16. C. C. Uphoff, Z.-B. Hu, S. M. Gignac et al., “Characterization of the monocyte-specific esterase (MSE) gene,” Leukemia, vol. 8, no. 9, pp. 1510–1526, 1994. View at: Google Scholar
  17. D. E. Kellogg and S. Kwok, “Detection of human immunodeficiency virus,” in PCR Protocols, M. A. Innis, D. H. Gelfand, J. J. Sninsky, and T. J. White, Eds., pp. 337–347, Academic Press, San Diego, Calif, USA, 1st edition, 1990. View at: Google Scholar
  18. S. Kwok, D. Kellogg, G. Ehrlich, B. Poiesz, S. Bhagavati, and J. J. Sninsky, “Characterization of a sequence of human T cell leukemia virus type I from a patient with chronic progressive myelopathy,” Journal of Infectious Diseases, vol. 158, no. 6, pp. 1193–1197, 1988. View at: Google Scholar
  19. I. Saito, B. Servenius, T. Compton, and R. I. Fox, “Detection of Epstein-Barr virus DNA by polymerase chain reaction in blood and tissue biopsies from patients with Sjogren's syndrome,” Journal of Experimental Medicine, vol. 169, no. 6, pp. 2191–2198, 1989. View at: Google Scholar
  20. C. C. Uphoff, A. Carbone, G. Gaidano, and H. G. Drexler, “HHV-8 infection is specific for cell lines derived from primary effusion (body cavity-based) lymphomas,” Leukemia, vol. 12, no. 11, pp. 1806–1809, 1998. View at: Google Scholar
  21. P. Pontisso, M. G. Ruvoletto, G. Fattovich et al., “Clinical and virological profiles in patients with multiple hepatitis virus infections,” Gastroenterology, vol. 105, no. 5, pp. 1529–1533, 1993. View at: Google Scholar
  22. I. Miyoshi, I. Kubonishi, and S. Yoshimoto, “Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells,” Nature, vol. 294, no. 5843, pp. 770–771, 1981. View at: Google Scholar
  23. A. Telenti, P. Imboden, and D. Germann, “Competitive polymerase chain reaction using an internal standard: application to the quantitation of viral DNA,” Journal of Virological Methods, vol. 39, no. 3, pp. 259–268, 1992. View at: Publisher Site | Google Scholar
  24. L. F. Lopes, M. M. Bacchi, D. Elgui-de-Oliveira, S. G. Zanati, M. Alvarenga, and C. E. Bacchi, “Epstein-Barr virus infection and gastric carcinoma in Sao Paulo State, Brazil,” Brazilian Journal of Medical and Biological Research, vol. 37, no. 11, pp. 1707–1712, 2004. View at: Google Scholar
  25. G. Ragona, I. Ernberg, and G. Klein, “Induction and biological characterization of the Epstein-Barr virus (EBV) carried by the Jijoye lymphoma line,” Virology, vol. 101, no. 2, pp. 553–557, 1980. View at: Google Scholar
  26. G. F. Bahr, U. Mikel, and G. Klein, “Localization and quantitation of EBV associated nuclear antigen (EBNA) in Raji cells,” Beitrage zur Pathologie, vol. 155, no. 1, pp. 72–78, 1975. View at: Google Scholar
  27. J. F. de Kroon, P. M. Kluin, H. C. Kluin-Nelemans, R. Willemze, and J. H. F. Falkenburg, “Homing and antigenic characterization of a human non-Hodgkin's lymphoma B cell line in severe combined immunodeficient (SCID) mice,” Leukemia, vol. 8, no. 8, pp. 1385–1391, 1994. View at: Google Scholar
  28. H. C. Kluin-Nelemans, J. Limpens, J. Meerabux et al., “A new non-Hodgkin's B-cell line (DoHH2) with a chromosomal translocation t(14;18)(q32;q21),” Leukemia, vol. 5, no. 3, pp. 221–224, 1991. View at: Google Scholar
  29. A. Carbone, A. M. Cilia, A. Gloghini et al., “Establishment of HHV-8-positive and HHV-8-negative lymphoma cell lines from primary lymphomatous effusions,” International Journal of Cancer, vol. 73, no. 4, pp. 562–569, 1997. View at: Google Scholar
  30. A. Carbone, A. M. Cilia, A. Gloghini et al., “Establishment and characterization of EBV-positive and EBV-negative primary effusion lymphoma cell lines harbouring human herpesvirus type-8,” British Journal of Haematology, vol. 102, no. 4, pp. 1081–1089, 1998. View at: Publisher Site | Google Scholar
  31. J. H. Schiller, G. Bittner, L. F. Meisner et al., “Establishment and characterization of an Epstein-Barr virus spontaneously transformed lymphocytic cell line derived from a hairy cell leukemia patient,” Leukemia, vol. 5, no. 5, pp. 399–407, 1991. View at: Google Scholar
  32. J. V. Melo, L. Foroni, V. Brito-Babapulle, L. Luzzatto, and D. Catovsky, “The establishment of cell lines from chronic B cell leukaemias: evidence of leukaemic origin by karyotypic abnormalities and Ig gene rearrangement,” Clinical and Experimental Immunology, vol. 73, no. 1, pp. 23–28, 1988. View at: Google Scholar
  33. D. Saltman, N. S. Bansal, F. M. Ross, J. A. Ross, G. Turner, and K. Guy, “Establishment of a karyotypically normal B-chronic lymphocytic leukemia cell line; evidence of leukemic origin by immunoglobulin gene rearrangement,” Leukemia Research, vol. 14, no. 4, pp. 381–387, 1990. View at: Publisher Site | Google Scholar
  34. L. Falk, L. Wolfe, and F. Deinhardt, “Epstein Barr virus: transformation of non human primate lymphocytes in vitro,” International Journal of Cancer, vol. 13, no. 3, pp. 363–376, 1974. View at: Google Scholar
  35. T. M. McCarty, S. Rajaraman, F. F. B. Elder, P. Gadson, and E. B. Thompson, “Establishment and characterization of a human myeloid cell line from Philadelphia chromosome-negative myeloblastic leukemia arising in a patient with myelodysplastic syndrome,” Blood, vol. 70, no. 5, pp. 1665–1672, 1987. View at: Google Scholar
  36. K. H. Th'ng, G. Garewal, and L. Kearney, “Establishment and characterization of three new malignant lymphoid cell lines,” International Journal of Cancer, vol. 39, no. 1, pp. 89–93, 1987. View at: Google Scholar
  37. J.-H. Gong, G. Maki, and H.-G. Klingemann, “Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells,” Leukemia, vol. 8, no. 4, pp. 652–658, 1994. View at: Google Scholar
  38. E. Grogan, H. Jenson, and J. Countryman, “Transfection of a rearranged viral DNA fragment, WZhet, stably converts latent Epstein-Barr viral infection to productive infection in lymphoid cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 5, pp. 1332–1336, 1987. View at: Google Scholar
  39. G. Miller, A. El-Guindy, J. Countryman, J. Ye, and L. Gradoville, “Lytic cycle switches of oncogenic human gammaherpesviruses(1),” Advances in Cancer Research, vol. 97, pp. 81–109, 2007. View at: Publisher Site | Google Scholar
  40. L. Gradoville, D. Kwa, A. El-Guindy, and G. Miller, “Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle,” Journal of Virology, vol. 76, no. 11, pp. 5612–5626, 2002. View at: Publisher Site | Google Scholar
  41. P. M. Lieberman, J. M. Hardwick, J. Sample, G. S. Hayward, and S. D. Hayward, “The Zta transactivator involved in induction of lytic cycle gene expression in Epstein-Barr virus-infected lymphocytes binds to both AP-1 and ZRE sites in target promoter and enhancer regions,” Journal of Virology, vol. 64, no. 3, pp. 1143–1155, 1990. View at: Google Scholar
  42. P. Di Francesco, A. Lisi, S. Rieti, V. Manni, S. Grimaldi, and E. Garaci, “Cocaine potentiates the switch between latency and replication of Epstein-Barr virus in Raji cells,” Biochemical and Biophysical Research Communications, vol. 264, no. 1, pp. 33–36, 1999. View at: Publisher Site | Google Scholar
  43. S. Gargano, D. Caporossi, G. Gualandi, and E. Calef, “Different localization of Epstein-Barr virus genome in two subclones of the Burkitt lymphoma cell line Namalwa,” Genes Chromosomes and Cancer, vol. 4, no. 3, pp. 205–210, 1992. View at: Publisher Site | Google Scholar
  44. J. Gao, X. Luo, K. Tang, X. Li, and G. Li, “Epstein-Barr virus integrates frequently into chromosome 4q, 2q, 1q and 7q of Burkitt's lymphoma cell line (Raji),” Journal of Virological Methods, vol. 136, no. 1-2, pp. 193–199, 2006. View at: Publisher Site | Google Scholar
  45. A. Henderson, S. Ripley, M. Heller, and E. Kieff, “Chromosome site for Epstein-Barr virus DNA in a Burkitt tumor cell line and in lymphocytes growth-transformed in vitro,” Proceedings of the National Academy of Sciences of the United States of America, vol. 80, no. 7 I, pp. 1987–1991, 1983. View at: Google Scholar
  46. M. Nonoyama and J. S. Pagano, “Homology between Epstein Barr virus DNA and viral DNA from Burkitt's lymphoma and nasopharyngeal carcinoma determined by DNA DNA reassociation kinetics,” Nature, vol. 242, no. 5392, pp. 44–47, 1973. View at: Google Scholar
  47. M. A. Sells, M.-L. Chen, and G. Acs, “Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 4, pp. 1005–1009, 1987. View at: Google Scholar
  48. N. Tay, S.-H. Chan, and E.-C. Ren, “Detection of integrated hepatitis B virus DNA in hepatocellular carcinoma cell lines by nonradioactive in situ hybridization,” Journal of Medical Virology, vol. 30, no. 4, pp. 266–271, 1990. View at: Publisher Site | Google Scholar
  49. T. S. Su, W.-L. Hwang, and Y. K. Yauk, “Characterization of hepatitis B virus integrant that results in chromosomal rearrangement,” DNA and Cell Biology, vol. 17, no. 5, pp. 415–425, 1998. View at: Google Scholar
  50. R. L. Heberling, S. T. Barker, and S. S. Kalter, “Oncornavirus: isolation from a squirrel monkey (Saimiri sciureus) lung culture,” Science, vol. 195, no. 4275, pp. 289–292, 1977. View at: Google Scholar
  51. M. Popovic, J. Ponten, and M. Grofova, “Detection of oncornavirus like particles in human cell lines derived from tumors of hemopoietic tissue,” Neoplasma, vol. 21, no. 6, pp. 619–627, 1974. View at: Google Scholar
  52. T. Oda, S. Ikeda, S. Watanabe, M. Hatsushika, K. Akiyama, and F. Mitsunobu, “Molecular cloning, complete nucleotide sequence, and gene structure of the provirus genome of a retrovirus produced in a human lymphoblastoid cell line,” Virology, vol. 167, no. 2, pp. 468–477, 1988. View at: Google Scholar
  53. T. Oda, M. Hatsushika, S. Watanabe et al., “Immunoelectron microscopic and immunoblotting analyses of a retrovirus produced in a human lymphoblastoid cell line with a monoclonal antibody,” Cellular and Molecular Biology, vol. 32, no. 3, pp. 343–350, 1986. View at: Google Scholar
  54. P. G. Middleton, S. Miller, J. A. Ross, C. M. Steel, and K. Guy, “Insertion of SMRV-H viral DNA at the c-myc gene locus of a BL cell line and presence in established cell lines,” International Journal of Cancer, vol. 52, no. 3, pp. 451–454, 1992. View at: Publisher Site | Google Scholar
  55. M. Miyazawa, Y. Yanai, and M. Kurimoto, “Squirrel monkey retrovirus (SMRV) sequence from an SMRV- negative cell line?” Journal of Hepatology, vol. 31, no. 5, pp. 967–968, 1999. View at: Publisher Site | Google Scholar
  56. C. Voelkel, A. Lührmann, C. Baum, and H. E. von der Leyen, “Retrovirus mediated hematopoietic gene therapy: a European regulatory perspective with special focus on the situation in Germany,” Cellular Therapy and Transplantation, vol. 1, no. 4, 2009. View at: Google Scholar

Copyright © 2010 Cord C. Uphoff et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.